Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct:99:233-242.
doi: 10.1016/j.ijid.2020.07.042. Epub 2020 Aug 3.

Marburg virus disease: A summary for clinicians

Mark G Kortepeter  1 , Kerry Dierberg  2 , Erica S Shenoy  3 , Theodore J Cieslak  4 ; Medical Countermeasures Working Group of the National Ebola Training and Education Center's (NETEC) Special Pathogens Research Network (SPRN)
Affiliations
Review

Marburg virus disease: A summary for clinicians

Mark G Kortepeter et al. Int J Infect Dis. 2020 Oct.

Abstract

Objectives: This article summarizes the countermeasures for Marburg virus disease, focusing on pathogenesis, clinical features and diagnostics. There is an emphasis on therapies and vaccines that have demonstrated, through their evaluation in nonhuman primates (NHPs) and/or in humans, potential for use in an emergency situation.

Methods: A standardized literature review was conducted on vaccines and treatments for Marburg virus disease, with a focus on human and nonhuman primate data published in the last five years. More detail on the methods that were used is summarized in a companion methods paper.

Results: The study identified six treatments and four vaccine platforms that have demonstrated, through their efficacy in NHPs, potential benefit for treating or preventing infection in humans.

Conclusion: Succinct summaries of Marburg countermeasures are provided to give the busy clinician a head start in reviewing the literature if faced with a patient with Marburg virus disease. Links to other authoritative sources of information are also provided.

Keywords: Antiviral countermeasure; Antiviral therapy; Ebola virus; Filovirus; Marburg virus; Treatment; Vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bauer M.P., Timen A., Vossen A.C.T.M., van Dissel J.T. Marburg haemorrhagic fever in returning travellers: an overview aimed at clinicians. Clin Microbiol Infect. 2019;21:e28–e31. - PubMed
    1. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C. Remdesivir for the treatment of Covid-19 – preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2007764. Online ahead of print. - DOI - PubMed
    1. Bixler S.L., Bocan T.M., Wells K., Wetzel K.S., Van Tongeren S.A., Dong L. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antivir Res. 2018;151:97–104. - PubMed
    1. Borchert M., Mulangu S., Swanepoel R., Libande M.L., Tshomba A., Kulidri A. Serosurvey on household contacts of Marburg hemorrhagic fever patients. Emerg Infect Dis. 2006;12:433–439. - PMC - PubMed
    1. Brauburger K., Hume A.J., Muhlberger E., Olejnik J. Forty-five years of Marburg virus research. Viruses. 2012;4:1878–1927. - PMC - PubMed

MeSH terms